News & Events
Cancer diagnostics firm Insight Genetics today announced that it has received a $193,000 Small Business Innovation Research contract from the National Cancer Institute (NCI) to develop a companion diagnostic test for drugs targeting mutations and fusions of anaplastic lymphoma kinase (ALK). The test, Insight ALK Resistance™, is being developed to meet a growing challenge within personalized cancer care: the development of tumor resistance to a prescribed drug.
A spinout of Genetic Assays, a clinical diagnostics services firm, Insight Genetics was established in late 2007 to pursue molecular testing, particularly for cancer. Initially housed in the CET Life Sciences Center, one of the company’s early advisors has been Stephan W. Morris, MD, an oncologist in the Department of Pathology at St. Jude Children’s Research Hospital, who is internationally recognized as the discoverer and a leading researcher on anaplastic lymphoma kinase (ALK). Read more.
Personalized medicine has grown more rapidly in the area of oncology than in any other large disease category, mostly due to greater scientific study of the role of specific genetic traits in cancer. Companion diagnostics are generating increasing development in personalized cancer care, offering the promise of matching a cancer therapy to a person’s disease at the molecular level. Read more.
The field of molecular diagnostics is becoming increasingly important across health care. Scientific discoveries related to key biomarkers combined with advances in molecular testing have enhanced our ability to diagnose, manage, and treat a range of medical conditions. Perhaps no clinical area has been more altered by molecular diagnostics than oncology.
Insight Genetics, Inc. presented a poster titled, “Insight ALK Screen™, a highly sensitive and specific RT-qPCR first-line screening assay for the comprehensive detection of all oncogenic anaplastic lymphoma kinase (ALK) fusions.” Authors included David Hout, John Handshoe and Josh Nickols of Insight Genetics, Stephan W. Morris and Liquan Xue of St. Jude Children’s Research Hospital, and Derek Bouman, Kameron Schmidt, Kenneth Bloom and Douglas Ross of Clarient/GE Healthcare, Inc.